• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

The RELAX-AHF-2 trial: serelaxin provides no mortality benefit in acute heart failure patients

byDayton McMillan
September 7, 2019
in Cardiology, Chronic Disease
Reading Time: 3 mins read
1
Share on FacebookShare on Twitter

1. Patients hospitalized with acute heart failure (AHF) randomized to receive the vasodilator serelaxin experienced similar occurrence of death from heart failure at 180 days compared to placebo treated patients.

2. A more immediate outcome, worsening of AHF at 5 days, also showed no benefit for serelaxin compared to placebo treatment.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Acute heart failure is a leading cause of hospitalization and notable morbidity and mortality occurs for patients following an AHF event. Relaxin is a physiologic hormone which contributes to vasodilation during pregnancy and has been considered a possible treatment for cardiovascular conditions. Serelaxin is a recombinant form of relaxin-2 and previously has been shown to lower incidence of AHF worsening during hospitalization, though mortality benefits were not fully evaluation. The second Relaxin in Acute Heart Failure (RELAX-AHF-2) trial compares patients randomized to serelaxin and placebo. The primary endpoints of cardiovascular mortality at 180 days and worsening of AHF at 5 days post-initial treatment showed not significant difference between serelaxin and placebo in either outcome. Blood pressure was notably lower in the treatment group. Both serious and overall adverse events occurred at similar rates between the two groups.

This large randomized study provides clarifying evidence for exploratory mortality outcomes in the RELAX-AHF trial, suggesting no mortality benefit for AHF patients treated with serelaxin. The trial was strengthened by its randomized design and large trial size but limited by the length of follow-up, as longer follow-up may have suggested some separation in treatment efficacy.

Click to read the study in NEJM

Relevant Reading: Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

RELATED REPORTS

Dapagliflozin efficacious and safe in treating heart failure

Interatrial shunt device not effective in patients with symptomatic heart failure

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

In-Depth [randomized controlled trial]: This double-blind, multicenter, randomized, placebo-controlled trial enrolled patients between 2013 and 2017. Eligible patients were adults hospitalized with AHF and dyspnea, had congestion on chest x-ray, had elevated brain natriuretic peptide levels, and were expected to receive intravenous therapy for at least 48 hours. Patients were randomized in a 1:1 ratio to 30 μg/kg/day of serelaxin for 48 hours (n=3274) or placebo (n=3271). If a patient’s systolic or absolute blood pressure was significantly deceased with treatment the dose was adjusted. Patients were assessed for the first 5 days of treatment or until discharge and then followed-up with out to 180 days. The primary outcomes were death from cardiovascular outcomes by 180 days and worsening of acute heart failure at 5 days. Treatment was discontinued in 21.9% and 15.7% of serelaxin and placebo patients, respectfully, due to hypotension. At 180 days death from cardiovascular causes occurred in 8.7% of serelaxin and 8.9% of placebo patients (hazard ratio, 0.98; 95% confidence interval [CI], 0.83 to 1.15; P=0.77). Worsening of AHF at 5 days occurred in 6.9% and 7.7% of serelaxin and placebo patients, respectfully (hazard ratio, 0.89; 95% CI, 0.75 to 1.07; P=0.19). Both per-protocol and intention-to-treat analysis showed similar efficacy results. The median length of hospitalization was similar in the two groups. Approximately half of patients in both groups experienced an adverse event in the first 5 days of treatment. Serious adverse events also occurred at similar rates between treatment and placebo groups.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: congestive heat failureheart failurerelaxinserelaxin
Previous Post

The NAMSAL ANRS 12313 trial: HIV viral suppression similar for dolutegravir and low-dose efavirenz treatment

Next Post

#VisualAbstract: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

RelatedReports

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Dapagliflozin efficacious and safe in treating heart failure

May 13, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
StudyGraphics

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

February 10, 2022
Cardiology

Sacubitril or valsartan versus standard medical therapies in patients with heart failure with preserved ejection fraction: PARALLAX trial

November 17, 2021
Next Post
#VisualAbstract: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

#VisualAbstract: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

#VisualAbstract: Liraglutide in Children and Adolescents with Type 2 Diabetes

#VisualAbstract: Liraglutide in Children and Adolescents with Type 2 Diabetes

Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ

Quick Take: Breast Cancer Recurrence in the Nipple-Areola Complex After Nipple-Sparing Mastectomy With Immediate Breast Reconstruction for Invasive Breast Cancer

Please login to join discussion

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.